Radiation-induced dysbiosis in a colorectal cancer mouse model

SCK•CEN Mentor

Wouters Shari, swouters@sckcen.be, +32 (0)14 33 88 35

Expert group

Microbiology

SCK•CEN Co-mentor

Ahmed Mohamed Mysara , mahmed@sckcen.be , +32 (0)14 33 28 36

Introduction

Colorectal cancer (CRC) is the second most common identified malignancy worldwide and thus represents an important health and socioeconomical burden. Recent data based on metagenomics and experimental models suggest a strong contribution of the gut microbiome in modulating CRC development. Various studies have systemically showed a significant shift in microbial composition comparing the gut microbiome of CRC patients with healthy individuals, a phenomenon commonly referred to as dysbiosis. Particularly, the presence of certain types of bacterial populations such as Bacteroides fragilis, Escherichia coli, and Fusobacterium nucleatum have been associated with an increased risk for the development of CRC, while other bacteria including Lachnospiraceae species seem to have an antitumor effect in the colon by producing metabolites such as short-chain fatty acid butyrate promoting apoptosis of colonic cancer cells.

Radiotherapy plays an adjuvant role in the treatment of CRC. However, the usage of radiotherapy has been shown to cause mucositis and radiation-induced ulceration which drive substantial changes in the gut microbiome leading to intestinal dysbiosis in CRC patients. This radiation‐induced toxicity and its association with microbial dynamics, forms a medical problem that urgently needs addressing in order to have an effective intervention.

Objective

The goal of this project is to gain novel insights in the dynamics of the gut, with a specific focus on the microbiome, upon exposure to radiation.

For this purpose, both healthy mice and mice with induced CRC (OAM/DSS mouse model) will be irradiated. Colon and faecal samples will be collected at different time points. To assess the microbial composition, samples will be analysed through 16S metagenetics combined with flow cytometry. In order to gain more insight into the pathological signature, samples will be analysed histologically and qPCR will be performed to assess multiple inflammation biomarkers.

The minimum diploma level of the candidate needs to be

Academic bachelor

The candidate needs to have a background in

Bio-engineering , Biology , Medical , or Biochemistry & Biotechnology

Estimated duration

6-9 months